{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:53:46Z","timestamp":1781783626926,"version":"3.54.5"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["H201628"],"award-info":[{"award-number":["H201628"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["2016103003"],"award-info":[{"award-number":["2016103003"]}],"id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81270769"],"award-info":[{"award-number":["81270769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000703"],"award-info":[{"award-number":["82000703"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20211054"],"award-info":[{"award-number":["BK20211054"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113701","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T18:25:28Z","timestamp":1663266328000},"page":"113701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Progress and prospects of Sacubitril\/Valsartan: Based on heart failure with preserved ejection fraction"],"prefix":"10.1016","volume":"155","author":[{"given":"Ruoyu","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.biopha.2022.113701_bib1","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1161\/CIR.0b013e31829e8807","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy","year":"2013","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.biopha.2022.113701_bib2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"9","key":"10.1016\/j.biopha.2022.113701_bib3","first-page":"833","article-title":"Committee of the report on cardiovascular health and diseases in China, report on cardiovascular health and diseases in China 2019: an updated summary","volume":"35","author":"A. The Writing","year":"2020","journal-title":"Chin. Circ. J."},{"issue":"22","key":"10.1016\/j.biopha.2022.113701_bib4","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Prospective randomized cumulative survival study, effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.biopha.2022.113701_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJM199108013250508","article-title":"ACE inhibitors \u2013 a cornerstone of the treatment of heart failure","volume":"325","author":"Braunwald","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.biopha.2022.113701_bib8","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","article-title":"CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure","volume":"13","author":"McMurray","year":"2011","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib9","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ehf2.12005","article-title":"Heart failure: preventing disease and death worldwide","volume":"1","author":"Ponikowski","year":"2014","journal-title":"ESC Heart Fail."},{"issue":"9851","key":"10.1016\/j.biopha.2022.113701_bib10","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"Prospective comparison of, The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.biopha.2022.113701_bib11","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart failure with preserved ejection fraction","volume":"375","author":"Redfield","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jacc.2011.10.873","article-title":"Increased proximal arterial stiffness and cardiac response with moderate exercise in patients with heart failure and preserved ejection fraction","volume":"59","author":"Tartiere-Kesri","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"15","key":"10.1016\/j.biopha.2022.113701_bib13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113701_bib14","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ijcard.2018.06.060","article-title":"Sacubitril\/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives","volume":"281","author":"Gori","year":"2019","journal-title":"Int. J. Cardiol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"issue":"17","key":"10.1016\/j.biopha.2022.113701_bib16","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.biopha.2022.113701_bib17","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2022.113701_bib19","unstructured":"A. Heart Failure Group of Chinese Society of Cardiology of Chinese Medical, A. Chinese Heart Failure Association of Chinese Medical Doctor, C. Editorial Board of Chinese Journal of, [Chinese guidelines for the diagnosis and treatment of heart failure 2018], Zhonghua Xin Xue Guan Bing Za Zhi 46(10), 2018, pp. 760\u2013789."},{"key":"10.1016\/j.biopha.2022.113701_bib20","unstructured":"A. General Practitioner Branch of Chinese Medical Doctor Association, Chinese Expert Consensus on Clinical Use of Sacubitril\/Valsartan for Cardiovascular Diseases in Primary Care, Chinese General Practice 24(23), 2021 2885\u20132890,2897."},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib21","first-page":"612","article-title":"expert consensus committee for the management of patients with heart failure with preserved ejection fraction and hypertension, Chinese experts' consensus on the management of patients with heart failure with preserved ejection fraction and hypertension","volume":"29","author":"Chinese","year":"2021","journal-title":"Chin. J. Hypertens."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1161\/01.HYP.0000258532.07418.fa","article-title":"Molecular biology of the natriuretic peptide system: implications for physiology and hypertension","volume":"49","author":"Gardner","year":"2007","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.amjhyper.2003.09.014","article-title":"Omapatrilat and enalapril in patients with hypertension: the omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial","volume":"17","author":"Kostis","year":"2004","journal-title":"Am. J. Hypertens."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib24","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1523-1755.2004.00982.x","article-title":"Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy","volume":"66","author":"Benigni","year":"2004","journal-title":"Kidney Int."},{"issue":"4727","key":"10.1016\/j.biopha.2022.113701_bib25","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.2932797","article-title":"Atrial natriuretic factor: a hormone produced by the heart","volume":"230","author":"de Bold","year":"1985","journal-title":"Science"},{"issue":"9061","key":"10.1016\/j.biopha.2022.113701_bib26","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S0140-6736(96)07424-7","article-title":"The natriuretic-peptide family","volume":"349","author":"Wilkins","year":"1997","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.biopha.2022.113701_bib27","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s40262-017-0543-3","article-title":"Clinical pharmacokinetics of Sacubitril\/Valsartan (LCZ696): a novel angiotensin receptor-neprilysin inhibitor","volume":"56","author":"Ayalasomayajula","year":"2017","journal-title":"Clin. Pharmacokinet."},{"issue":"13","key":"10.1016\/j.biopha.2022.113701_bib28","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib29","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib30","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"Maddox","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2022.113701_bib31","unstructured":"A. Chinese Medical Association, A. Chinese Medical Journals Publishing House, A. Chinese Society of General Practice, A. Editorial Board of Chinese Journal of General Practitioners of Chinese Medical Association, A. Expert Group of Guidelines for Primary Care of Cardiovascular Disease, Guideline for primary care of chronic heart failure(2019), Chin. J. Gen. Pract. 18(10), 2019, 936\u2013947."},{"key":"10.1016\/j.biopha.2022.113701_bib32","unstructured":"A. Beijing Hypertension Prevention and treatment Association, A. Beijing Diabetes Prevention and treatment Association, A. Beijing Society for chronic Disease Prevention and Health Education, A. Hypertension Alliance, A. Professional Committee for the aged and Health of China Geriatric Health Association, A. National Geriatric Disease Clinical Research Center China Alliance for Prevention and treatment of Geriatric Cardiovascular Diseases, Practical Guidelines for the Comprehensive Management of Primary Cardiovascular Diseases 2020, Chinese Journal of the Frontiers of Medical Science (Electronic Version) 12(8), 2020, 1\u201373."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib33","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"38","author":"Unger","year":"2020","journal-title":"J. Hypertens."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib34","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/cvr\/cvs353","article-title":"Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction","volume":"97","author":"Hamdani","year":"2013","journal-title":"Cardiovasc. Res."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib35","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1161\/CIRCHEARTFAILURE.113.000539","article-title":"Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model","volume":"6","author":"Hamdani","year":"2013","journal-title":"Circ. Heart Fail."},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib36","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib37","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1161\/CIRCRESAHA.114.301286","article-title":"Gigantic business: titin properties and function through thick and thin","volume":"114","author":"Linke","year":"2014","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib38","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1161\/CIRCRESAHA.108.184408","article-title":"Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs","volume":"104","author":"Kruger","year":"2009","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib39","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib41","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/01.CIR.0000155257.33485.6D","article-title":"Cardiomyocyte stiffness in diastolic heart failure","volume":"111","author":"Borbely","year":"2005","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.biopha.2022.113701_bib42","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1161\/CIRCULATIONAHA.111.025270","article-title":"Diabetes mellitus worsens diastolic left ventricular dysfunction in aortic stenosis through altered myocardial structure and cardiomyocyte stiffness","volume":"124","author":"Falcao-Pires","year":"2011","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchf.2015.10.007","article-title":"Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction","volume":"4","author":"Franssen","year":"2016","journal-title":"JACC Heart Fail."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib44","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.jacc.2017.12.008","article-title":"Noncanonical role for calcineurin in pressure-induced cardiac hypertrophy","volume":"71","author":"Shaw","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"23","key":"10.1016\/j.biopha.2022.113701_bib45","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1161\/CIRCULATIONAHA.104.510594","article-title":"Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides","volume":"111","author":"Tokudome","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.113701_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2022.04.006","article-title":"Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril\/valsartan. Position Paper of the Italian Society of Cardiology","author":"Perrone-Filardi","year":"2022","journal-title":"Eur. J. Intern. Med."},{"issue":"9386","key":"10.1016\/j.biopha.2022.113701_bib47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.biopha.2022.113701_bib48","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.biopha.2022.113701_bib49","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","article-title":"The perindopril in elderly people with chronic heart failure (PEP-CHF) study","volume":"27","author":"Cleland","year":"2006","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib50","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","article-title":"Aldosterone and end-organ damage","volume":"14","author":"Brown","year":"2005","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib51","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s10741-018-9758-0","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials","volume":"24","author":"Kapelios","year":"2019","journal-title":"Heart Fail. Rev."},{"issue":"8","key":"10.1016\/j.biopha.2022.113701_bib52","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2020.01.009","article-title":"Meta-analysis evaluating the effects of renin-angiotensin-aldosterone system blockade on outcomes of heart failure with preserved ejection fraction","volume":"125","author":"Kuno","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib53","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/eurjhf\/hfr161","article-title":"Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study","volume":"14","author":"Conraads","year":"2012","journal-title":"Eur. J. Heart Fail."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib54","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/eurjhf\/hfs141","article-title":"Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese diastolic heart failure study (J-DHF)","volume":"15","author":"Yamamoto","year":"2013","journal-title":"Eur. J. Heart Fail."},{"issue":"19","key":"10.1016\/j.biopha.2022.113701_bib55","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of Sacubitril\/Valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the PARALLAX randomized clinical trial","volume":"326","author":"Pieske","year":"2021","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.biopha.2022.113701_bib56","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/j.jacc.2007.09.021","article-title":"Natriuretic peptides","volume":"50","author":"Daniels","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.biopha.2022.113701_bib57","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1161\/01.CIR.0000020500.77568.3C","article-title":"Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study","volume":"105","author":"Mitchell","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib58","article-title":"What the near future holds for sacubitril\/valsartan: a summary of major ongoing studies","volume":"9","author":"Badreldin","year":"2022","journal-title":"J. Cardiovasc Dev. Dis."},{"issue":"11 Pt 1","key":"10.1016\/j.biopha.2022.113701_bib59","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.amjhyper.2004.05.027","article-title":"Validation of the transfer function technique for generating central from peripheral upper limb pressure waveform","volume":"17","author":"Gallagher","year":"2004","journal-title":"Am. J. Hypertens."},{"issue":"9722","key":"10.1016\/j.biopha.2022.113701_bib60","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib61","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/HYPERTENSIONAHA.113.02002","article-title":"Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study","volume":"63","author":"Kario","year":"2014","journal-title":"Hypertension"},{"issue":"9116","key":"10.1016\/j.biopha.2022.113701_bib62","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(05)77712-6","article-title":"Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. the international ecadotril multi-centre dose-ranging study investigators","volume":"351","author":"Cleland","year":"1998","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib63","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.5114\/aoms.2017.68813","article-title":"The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril\/valsartan","volume":"13","author":"Yandrapalli","year":"2017","journal-title":"Arch. Med. Sci."},{"issue":"44","key":"10.1016\/j.biopha.2022.113701_bib64","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/eurheartj\/ehx525","article-title":"The effect of sacubitril\/valsartan compared to olmesartan on cardiovascular remodelling in subjects with essential hypertension: the results of a randomized, double-blind, active-controlled study","volume":"38","author":"Schmieder","year":"2017","journal-title":"Eur. Heart J."},{"issue":"10","key":"10.1016\/j.biopha.2022.113701_bib65","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Prospective comparison of, I. Morbidity in heart failure, efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.biopha.2022.113701_bib66","unstructured":"A. Novartis Pharmaceuticals, Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF), \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03988634\u3009, 2022."},{"key":"10.1016\/j.biopha.2022.113701_bib67","unstructured":"D. Zhang, The Effect of Angiotensin Receptor-Neprilysin Inhibition on Cardiac Fibrosis in Patients With HFpEF, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05089539\u3009, 2021."},{"key":"10.1016\/j.biopha.2022.113701_bib68","unstructured":"A. Gvozdeva, LCZ696 in Advanced LV Hypertrophy and HFpEF, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03928158\u3009, 2022."},{"key":"10.1016\/j.biopha.2022.113701_bib69","unstructured":"M. Ledwidge, Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04687111\u3009, 2021."},{"key":"10.1016\/j.biopha.2022.113701_bib70","unstructured":"P. Arora, PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04971720\u3009, 2022."},{"key":"10.1016\/j.biopha.2022.113701_bib71","unstructured":"J. Wang, Sacubitril\/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04929600\u3009, 2021."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib72","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/ehjcvp\/pvab030","article-title":"Renal protection in chronic heart failure: focus on sacubitril\/valsartan","volume":"7","author":"Pontremoli","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"11","key":"10.1016\/j.biopha.2022.113701_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112629","article-title":"Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications","volume":"20","author":"Tanase","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib74","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/ejhf.799","article-title":"Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides","volume":"19","author":"D'Elia","year":"2017","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib75","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ejhf.2471","article-title":"Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the heart failure association of the European society of cardiology","volume":"24","author":"Mullens","year":"2022","journal-title":"Eur. J. Heart Fail."},{"issue":"10","key":"10.1016\/j.biopha.2022.113701_bib76","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/00004872-198810000-00003","article-title":"The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man","volume":"6","author":"McMurray","year":"1988","journal-title":"J. Hypertens."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib77","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00004872-199816020-00016","article-title":"Influence of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on renal sodium and water handling and albuminuria during infusion of atrial natriuretic factor into healthy volunteers","volume":"16","author":"Vervoort","year":"1998","journal-title":"J. Hypertens."},{"issue":"8","key":"10.1016\/j.biopha.2022.113701_bib78","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/(SICI)1096-9136(199808)15:8<678::AID-DIA639>3.0.CO;2-K","article-title":"Atrial natriuretic peptide increases urinary albumin excretion in men with type 1 diabetes mellitus and established microalbuminuria","volume":"15","author":"Prasad","year":"1998","journal-title":"Diabet. Med."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib79","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1053\/ajkd.2002.33907","article-title":"Atrial natriuretic peptide-induced microalbuminuria is associated with endothelial dysfunction in noncomplicated type 1 diabetes patients","volume":"40","author":"Vervoort","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib80","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11845-007-0030-1","article-title":"Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes","volume":"176","author":"Moore","year":"2007","journal-title":"Ir. J. Med. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1042\/cs0770643","article-title":"Effect of alpha-human atrial natriuretic peptide on proteinuria in patients with primary glomerular diseases","volume":"77","author":"Ishi","year":"1989","journal-title":"Clin. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib82","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/ki.1997.396","article-title":"Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure","volume":"52","author":"Lipkin","year":"1997","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib83","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000045836","article-title":"C-Type natriuretic peptide inhibits proliferation and monocyte chemoattractant protein-1 secretion in cultured human mesangial cells","volume":"86","author":"Osawa","year":"2000","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib84","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1161\/01.HYP.35.4.971","article-title":"Effects of cardiac natriuretic peptides on oxidized low-density lipoprotein- and lysophosphatidylcholine-induced human mesangial cell migration","volume":"35","author":"Kohno","year":"2000","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib85","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1046\/j.1523-1755.1998.00895.x","article-title":"C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo","volume":"53","author":"Canaan-Kuhl","year":"1998","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib86","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/PL00005140","article-title":"C-type natriuretic peptide inhibits rat mesangial cell proliferation by a phosphorylation-dependent mechanism","volume":"357","author":"Segawa","year":"1998","journal-title":"Naunyn Schmiede Arch. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113701_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174288","article-title":"Sacubitril\/valsartan in chronic kidney disease: from pharmacological mechanism to clinical application","volume":"907","author":"Kuang","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"16","key":"10.1016\/j.biopha.2022.113701_bib88","doi-asserted-by":"crossref","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","article-title":"Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American heart association","volume":"139","author":"Rangaswami","year":"2019","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.biopha.2022.113701_bib89","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrcardio.2014.83","article-title":"The pathophysiology of heart failure with preserved ejection fraction","volume":"11","author":"Borlaug","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"issue":"14","key":"10.1016\/j.biopha.2022.113701_bib90","first-page":"e391","volume":"119","author":"Hunt","year":"2009","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.biopha.2022.113701_bib91","first-page":"568","article-title":"ANMCO position paper on sacubitril\/valsartan in the management of patients with heart failure","volume":"19","author":"Di Tano","year":"2018","journal-title":"G Ital. Cardiol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib92","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib93","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib94","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib95","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s11739-019-02028-0","article-title":"Is echocardiography mandatory for patients with chronic kidney disease?","volume":"14","author":"Nardi","year":"2019","journal-title":"Intern Emerg. Med."},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib96","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/ndt\/gfz058","article-title":"2-chronic kidney disease, heart failure and neprilysin inhibition","volume":"35","author":"Haynes","year":"2020","journal-title":"Nephrol. Dial. Transpl."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib97","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1002\/ehf2.13002","article-title":"Effect of sacubitril\/valsartan on renal function: a systematic review and meta-analysis of randomized controlled trials","volume":"7","author":"Spannella","year":"2020","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.biopha.2022.113701_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175053","article-title":"Effect of Sacubitril\/Valsartan on renal function in patients with chronic kidney disease and heart failure with preserved ejection fraction: a real-world 12-week study","volume":"928","author":"Jia","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib99","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/ejhf.510","article-title":"Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey","volume":"18","author":"Komajda","year":"2016","journal-title":"Eur. J. Heart Fail."},{"issue":"11","key":"10.1016\/j.biopha.2022.113701_bib100","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jacc.2014.01.087","article-title":"Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment","volume":"64","author":"Damman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"20","key":"10.1016\/j.biopha.2022.113701_bib101","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.biopha.2022.113701_bib102","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1681\/ASN.2006010063","article-title":"Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction","volume":"17","author":"Jose","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib103","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"6-renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman","year":"2018","journal-title":"JACC Heart Fail."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib104","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0006-291X(90)90744-8","article-title":"Atrial natriuretic peptide regulation of endothelial permeability is mediated by cGMP","volume":"172","author":"Lofton","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib105","doi-asserted-by":"crossref","first-page":"F24","DOI":"10.1152\/ajprenal.00347.2010","article-title":"Transient and sustained increases in glomerular permeability following ANP infusion in rats","volume":"300","author":"Axelsson","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib106","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jchf.2018.02.017","article-title":"Exploiting the natriuretic peptide pathway to preserve glomerular filtration in heart failure","volume":"6","author":"Mullens","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"3 Pt 2","key":"10.1016\/j.biopha.2022.113701_bib107","first-page":"F415","article-title":"Direct vasodilatory action of atrial natriuretic factor on canine glomerular afferent arterioles","volume":"255","author":"Ohishi","year":"1988","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2022.113701_bib108","unstructured":"S. Liu, Efficacy and Safety of Sacubitril\/Valsartan in Maintenance Hemodialysis Patients With Heart Failure, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04458285\u3009, 2020."},{"key":"10.1016\/j.biopha.2022.113701_bib109","unstructured":"XUYI, The Effect of Sacubitril\/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT04572724\u3009, 2020."},{"key":"10.1016\/j.biopha.2022.113701_bib110","unstructured":"X. Du, Observation on the Effect of Sacubitril\/Valsartan in Advanced Chronic Kidney Disease\uff08CKD\uff09Patients With Heart Failure, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT03771729\u3009, 2018."},{"key":"10.1016\/j.biopha.2022.113701_bib111","unstructured":"G. Xing, Roxadustat Combined With Sacubitril Valsartan Sodium Tablets in the Treatment of Cardiorenal Anemia Syndrome, \u3008https:\/\/ClinicalTrials.gov\/show\/NCT05053893\u3009, 2021."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib112","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2018.10.059","article-title":"High-density lipoprotein particle subfractions in heart failure with preserved or reduced ejection fraction","volume":"73","author":"Hunter","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCULATIONAHA.116.021884","article-title":"Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap","volume":"134","author":"Shah","year":"2016","journal-title":"Circulation"},{"issue":"22","key":"10.1016\/j.biopha.2022.113701_bib114","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib115","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12968-018-0511-6","article-title":"The interplay between metabolic alterations, diastolic strain rate and exercise capacity in mild heart failure with preserved ejection fraction: a cardiovascular magnetic resonance study","volume":"20","author":"Mahmod","year":"2018","journal-title":"J. Cardiovasc. Magn. Reson."},{"issue":"24","key":"10.1016\/j.biopha.2022.113701_bib116","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1161\/CIRCULATIONAHA.119.039610","article-title":"Preservation of acyl coenzyme A attenuates pathological and metabolic cardiac remodeling through selective lipid trafficking","volume":"139","author":"Goldenberg","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib117","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005708","article-title":"Plasma ceramides and sphingomyelins in relation to heart failure risk","volume":"12","author":"Lemaitre","year":"2019","journal-title":"Circ. Heart Fail."},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib118","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","article-title":"Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial","volume":"5","author":"Solomon","year":"2017","journal-title":"JACC Heart Fail."},{"issue":"12","key":"10.1016\/j.biopha.2022.113701_bib119","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.2337\/db08-0649","article-title":"Atrial natriuretic peptide induces postprandial lipid oxidation in humans","volume":"57","author":"Birkenfeld","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2022.113701_bib120","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1038\/ncomms8235","article-title":"Stimulation of soluble guanylyl cyclase protects against obesity by recruiting brown adipose tissue","volume":"6","author":"Hoffmann","year":"2015","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2022.113701_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-55680-z","article-title":"Association between cardiac natriuretic peptides and lipid profile: a systematic review and meta-analysis","volume":"9","author":"Spannella","year":"2019","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib122","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-8587(17)30087-6","article-title":"Effect of sacubitril\/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial","volume":"5","author":"Seferovic","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"17","key":"10.1016\/j.biopha.2022.113701_bib123","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022069","article-title":"Effects of Sacubitril\/Valsartan on serum lipids in heart failure with preserved ejection fraction","volume":"10","author":"Selvaraj","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"24","key":"10.1016\/j.biopha.2022.113701_bib124","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.013149","article-title":"Associations between the cyclic guanosine monophosphate pathway and cardiovascular risk factors: MESA","volume":"8","author":"Ying","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20020245","article-title":"PCSK9 is expressed in human visceral adipose tissue and regulated by insulin and cardiac natriuretic peptides","volume":"20","author":"Bordicchia","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2022.113701_bib126","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1373\/clinchem.2011.167361","article-title":"Purified anthocyanin supplementation improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals","volume":"57","author":"Zhu","year":"2011","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib127","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3945\/ajcn.2009.27814","article-title":"Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects","volume":"90","author":"Qin","year":"2009","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.biopha.2022.113701_bib128","doi-asserted-by":"crossref","unstructured":"E. National Cholesterol Education Program Expert Panel on Detection, A. Treatment of High Blood Cholesterol in, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation 106(25), 2002, 3143\u20133421.","DOI":"10.1161\/circ.106.25.3143"},{"key":"10.1016\/j.biopha.2022.113701_bib129","unstructured":"P. European Association for Cardiovascular, Rehabilitation, Z. Reiner, A.L. Catapano, G. De Backer, I. Graham, M.R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M.J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P.P. Filardi, G. Riccardi, R.F. Storey, D. Wood, E.S.C.C.f.P. Guidelines, Committees, ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Eur Heart J 32(14), 2011, 1769\u20131818."},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib130","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/ejhf.115","article-title":"Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"16","author":"McMurray","year":"2014","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib131","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib132","doi-asserted-by":"crossref","first-page":"787","DOI":"10.2217\/14622416.8.7.787","article-title":"Role of OATP transporters in the disposition of drugs","volume":"8","author":"Niemi","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1016\/j.biopha.2022.113701_bib133","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2022.113701_bib134","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/jcpt.12408","article-title":"In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril\/valsartan (LCZ696)","volume":"41","author":"Ayalasomayajula","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib135","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ejhf.1342","article-title":"Effects of sacubitril\/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study","volume":"21","author":"Nougue","year":"2019","journal-title":"Eur. J. Heart Fail."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib136","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/cpt.455","article-title":"Improved insulin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension","volume":"101","author":"Jordan","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2022.113701_bib137","first-page":"413","article-title":"China heart failure registry study \u2013 a multicenter, prospective investigation for preliminary analysis on etiology, clinical features and treatment in heart failure patients","volume":"30","author":"Zhang","year":"2015","journal-title":"Chin. Circ. J."},{"issue":"2","key":"10.1016\/j.biopha.2022.113701_bib138","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur. J. Heart Fail."},{"issue":"3","key":"10.1016\/j.biopha.2022.113701_bib139","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.biopha.2022.113701_bib140","first-page":"984","article-title":"Left ventricular concentric remodeling is associated with decreased global and regional systolic function: the multi-ethnic study of atherosclerosis","volume":"112","author":"Rosen","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2022.113701_bib141","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2016.03.080","article-title":"The pathophysiological role of natriuretic peptide-RAAS cross talk in heart failure","volume":"226","author":"Rossi","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"19","key":"10.1016\/j.biopha.2022.113701_bib142","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.jacc.2009.05.015","article-title":"The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications","volume":"54","author":"Triposkiadis","year":"2009","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222010903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:31:37Z","timestamp":1781782297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222010903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":142,"alternative-id":["S0753332222010903"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113701","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress and prospects of Sacubitril\/Valsartan: Based on heart failure with preserved ejection fraction","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113701"}}